ClinicalTrials.gg
RecruitingNCT04987892IMPACTUpdated Apr 25, 2023

Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH

A Phase 4 interventional study of UroLift System and Tamsulosin Hydrochloride in BPH, sponsored by NeoTract, Inc.. Recruiting at 1 site in United States. Open to male participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-25.

Sponsored by NeoTract, Inc. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Study summary

This prospective, multicenter, two-arm, 1:1 randomized controlled trial (RCT) will enroll approximately 250 males at approximately 25 sites located within the United States. All enrolled subjects will be 45 years of age or older diagnosed with symptomatic benign prostatic hyperplasia (BPH). They will be randomized to one of two readily available, marketed BPH therapies; Prostatic Urethral Lift procedure with the UroLift System (PUL Arm) or 0.4mg tamsulosin HCl (MED Arm).

Read the detailed description

This prospective, multicenter, two-arm, 1:1 randomized controlled trial (RCT) will enroll approximately 250 males at approximately 25 sites located within the United States. All enrolled subjects will be 45 years of age or older diagnosed with symptomatic benign prostatic hyperplasia (BPH). They will be randomized to one of two readily available, marketed BPH therapies; Prostatic Urethral Lift procedure with the UroLift System (PUL Arm) or 0.4mg tamsulosin HCl (MED Arm).Men 45 or older diagnosed with symptomatic benign prostatic hyperplasia (BPH). BPH symptoms may range from mild (8) to severe (35) on the IPSS scale. All enrolled men must meet selection criteria and be candidates for therapy with both UroLift System and 0.4 mg tamsulosin HCl.

02

Conditions studied

  • BPH
03

In context

Lead sponsor

NeoTract, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male 45 years of age or older
  2. Diagnosis of BPH
  3. Experiencing symptoms of BPH as indicated by an IPSS ≥8 and ≤30
  4. Willing to wash out of current BPH medication(s), as applicable
  5. An appropriate candidate for both BPH therapies evaluated in this study.
  6. Ability to understand and consent to participate in this study
  7. Willing and able to participate in follow-up evaluations

Exclusion criteria

Exclusion Criteria:

  1. Use of alpha blocker for BPH unless washed-out for 30 days
  2. Use of daily phosphodiesterase type 5 inhibitor (PDE5i) for BPH unless washed-out for 30 days
  3. 5-alpha-reductase inhibitors for BPH used within 6 months of therapy initiation
  4. Current urinary tract infection or prostatitis
  5. Current gross hematuria
  6. Urinary incontinence presumed due to incompetent sphincter
  7. Catheter-dependent urinary retention within 1 month prior to enrollment
  8. Prostate volume greater than 100 cc as measured by TRUS
  9. Prostate specific antigen level of greater than 10 ng/ml within one year of enrollment unless prostate cancer has been ruled out
  10. History of neurogenic or atonic bladder
  11. History prostate cancer treatment
  12. Known to be hypersensitive to tamsulosin HCl or any component of tamsulosin HCl capsules
  13. Known allergy to nickel, titanium, or stainless steel
  14. Prior minimally invasive or surgical intervention for BPH
  15. Urethral conditions that may prevent insertion of delivery system into bladder.
  16. Currently enrolled in any other clinical research trial that has not completed the primary endpoint
  17. History of medical, surgical or other conditions that, in the opinion of the investigator, would interfere with the treatment or evaluation of the subject
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Prostatic Lift

    Treatment with the UroLift System

    Device: UroLift System

  • Active comparator
    Medication

    Treatment with Tamsulosin HCl 0.4mg

    Drug: Tamsulosin Hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Paired comparison of International Prostate Symptom Score (IPSS) percent change

    The primary study analysis compares the change in BPH symptoms in the PUL Arm to the change in BPH symptoms in the MED Arm measured 3 months after BPH therapy initiation. This will be measure by International Prostate Symptom Score (IPSS) percent change. IPSS ranges from 0-35, healthier patients have lower scores than patients more effected by BPH symptoms.

    Time frame: 3 Months after Therapy Initiation

Secondary outcomes

  1. Change in Quality of Life (QoL)

    The secondary analysis assesses the change in quality of life (QoL) due to urinary symptoms between the PUL and MED Arms measured 3 months after initiation of BPH therapy. This will be measured by change in QoL, ranging from 0-6. Healthier patients have lower scores than patients more effected by BPH symptoms.

    Time frame: 3 months after BPH Therapy Initiation

07

Study locations

1 of 1 sites recruiting
  • Neotract
    Pleasanton, California 94588, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for May 2025, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2021
First posted
Aug 3, 2021
StartActual
Dec 6, 2021
Primary completionEst.
May 2025
CompletionEst.
Oct 2025
Last update
Apr 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04987892
Lead sponsor
NeoTract, Inc.
Responsible party
Sponsor
First posted
Aug 3, 2021
Start date
Dec 6, 2021
Primary completion
May 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Apr 25, 2023

Study contacts

Rogers Mitchell
Contact
rogers.mitchell@neotract.com
805-403-7107
Claus Roehrborn, M.D.
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion